Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377402 | 0.87 | ERAP1 (0.55) | ERAP1PTGS1PTGS2POLBPTPN5 | |
| SCHEMBL5377375 | 0.73 | SMN1; SMN2 (0.56) | ERAP1POLBLMNAMAPTHTT | |
| SCHEMBL2254318 | 0.72 | ERAP1 (0.51) | ERAP1PTGS1PTGS2POLBPTPN5 | |
| SCHEMBL10966990 | 0.71 | LTA4H (0.57) | ERAP1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5373132 | 0.69 | SMN1; SMN2 (0.50) | LMNAMAPTHTTMAPK1SMN1; SMN2 | |
| SCHEMBL9718488 | 0.69 | LTA4H (0.53) | ERAP1PTGS1PTGS2PTPN5LMNA | |
| SCHEMBL15455608 | 0.68 | LTA4H (0.57) | ERAP1LMNAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL16049872 | 0.68 | ERAP1 (0.50) | ERAP1PTGS1PTGS2POLBLMNA | |
| SCHEMBL20777399 | 0.68 | GAA (0.51) | ERAP1POLBPTPN5MEN1KMT2A | |
| SCHEMBL3998037 | 0.68 | IDH1 (0.48) | ERAP1LMNASMN1; SMN2NPSR1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271153-B2 | Treating diseases associated with hyperglycemia such as diabetes; SGLT2 (sodium/glucose cotransporter 2) inhibitor; 3-(4-Ethylbenzyl)-2-(beta-D-glucopyranosyloxy)-4,6-dimethyl-pyridine for example | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1405859-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | GPR119, NPR3, SLC5A2 | ERAP1 1512/4885PTGS1 768/4885PTGS2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.